Advanced search
Publication Cover
Expert Review of Anticancer Therapy Volume 22, 2022 - Issue 4
Submit an article Journal homepage
622
Views
4
CrossRef citations to date
0
Altmetric
Drug Profile

Current and emerging role of sacituzumab govitecan in the management of urothelial carcinoma

Vinay Mathew ThomasDivision of Oncology, Department of Internal Medicine, Huntsman Cancer Institute, University of Utah, Salt Lake City, Utah
,
Nishita TripathiDivision of Oncology, Department of Internal Medicine, Huntsman Cancer Institute, University of Utah, Salt Lake City, Utah
,
Neeraj AgarwalDivision of Oncology, Department of Internal Medicine, Huntsman Cancer Institute, University of Utah, Salt Lake City, Utah
&
Umang SwamiDivision of Oncology, Department of Internal Medicine, Huntsman Cancer Institute, University of Utah, Salt Lake City, UtahCorrespondence[email protected]
Pages 335-341 | Received 05 Jan 2022, Accepted 02 Mar 2022, Published online: 10 Mar 2022

Citations (4)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (1)

Muhammad Ashir Shafique, Abdul Haseeb, Mohammad Arham Siddiq, Abdullah Mussarat, Hussain Sohail Rangwala & Muhammad Saqlain Mustafa. (2023) Current and Emerging Treatments for Urothelial Carcinoma: A Focus on Enfortumab Vedotin. Cancer Management and Research 15, pages 699-706.
Read now

Articles from other publishers (3)

David Alex Goodson & Terence W. Friedlander. (2023) The Future of Antibody–Drug Conjugates in Urothelial Cancer. Advances in Oncology 3:1, pages 137-159.
Crossref
Bartosz Małkiewicz, Adam Gurwin, Jakub Karwacki, Krystian Nagi, Klaudia Knecht-Gurwin, Krzysztof Hober, Magdalena Łyko, Kamil Kowalczyk, Wojciech Krajewski, Anna Kołodziej & Tomasz Szydełko. (2022) Management of Bladder Cancer Patients with Clinical Evidence of Lymph Node Invasion (cN+). Cancers 14:21, pages 5286.
Crossref
Jiří Hatina, Michaela Kripnerová, Kateřina Houfková, Martina Hajdůšková, Nazila Navvabi, Natálie Havlíčková & Martin Pešta. 2022.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.